References
- Mieth H. The early development of allylamine antimycotics. J Dermatol Treat 1990; 1(Suppl 2)5–6
- Clayton Y M. The in vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101–3
- Haroon T S., Hussain I, Mahmood A, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry, non-inflammatory tinea capitis. Br J Dermatol 1992; 126(Suppl 39)47–50
- Becker L E. Griseofulvin. Dermatologic clinics, E B. Smith. W. B. Saunders Company, Philadelphia 1984; 115–20
- Ryder N S. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98–100
- Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 1990; 71: 322–6
- Villars V, Jones T C. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatol Treat 1990; 1(Suppl 2)33–8
- Schuster I, Ryder N S. Allylamines-mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms. J Dermatol Treat 1990; 1(Suppl 2)7–9